adalimumab vs etanercept

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

NCT03780959 · Phase 2/3 · completed

After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.

NCT00195676 · Phase 3 · completed

Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.